Metabolic & Cardiometabolic
metformin decreases cancer incidence
In plain terms: Does metformin reduce cancer risk?
Contested Metabolic & Cardiometabolic 🔬 Includes disconfirming
Part of: 💊 metformin
RefutedContestedStrong support
consensus score -0.09
Contested — observational cohorts and their meta-analyses suggest lower cancer incidence, but those associations are heavily confounded by time-related (immortal-time) bias, and bias-corrected analyses, target-trial emulations, and the one cancer-endpoint RCT show little or no true effect.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
6 support 6 contradict 2 tested null 8 mixed · 22 sources, 11 independent groups
The evidence (22)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ansar F et al 2026 · Qeios | observational | supports | moderate | Meta-analysis of 2 RCTs, n=405, non-diabetic post-polypectomy adults. Metformin reduced 1y colorectal adenoma recurrence: RR 0.61 (0.48-0.78), low risk of bias. |
| Nie Z et al] # corrected 2026-08-17 from PubMed; was [Liu 2016 · Pharm Biol | meta-analysis | supports | low | Meta of observational studies: metformin associated with reduced colorectal cancer incidence in T2D; observational-only, susceptible to bias. |
| Lee HS et al 2026 · study_type: observational | observational | supports | low | Retrospective cohort, T2D endoscopy patients, Korea. Metformin (no insulin) assoc w/ lower gastric adenocarcinoma incidence; no effect on dysplasia. |
| Feng Y et al 2026 · study_type: observational | observational | supports | low | Two-sample Mendelian randomization (IVW), GWAS-derived SNP instruments. Genetically-proxied metformin exposure assoc w/ lower lung cancer risk: OR 0.249 (0.065-0.950, P=0.041). |
| Col 2012 · Breast Cancer Res Treat | meta-analysis | mixed | moderate | Breast cancer meta + critical review: apparent risk reduction but authors explicitly flag methodological bias undermining the association. |
| Getu MA et al 2026 · study_type: meta-analysis | meta-analysis | mixed | moderate | Meta-analysis, 18 studies (10 cohort+8 RCT), 1.3M participants. OS HR 1.02 (0.80-1.30, ns); PFS HR 1.00 (0.76-1.31, ns); but cancer incidence HR 0.90 (0.86-0.94, reduced). |
| Suissa 2023 · Diabetes Care | observational | contradicts | high | \"Real-world evidence failure\": re-analysis shows metformin's reported cancer benefit is an artifact of biased designs; properly designed studies show no effect. |
| Huang Y et al 2026 · study_type: observational | observational | contradicts | high | Swedish nationwide cohort, n=744,173, Cox regression. Metformin assoc w/ INCREASED HCC risk (HR 1.15, 95%CI 1.02-1.30); decreased in obesity subgroup (HR 0.56); null for cholangiocarcinoma. |
| Campbell 2017 · Ageing Res Rev | meta-analysis | mixed | low | Meta reports lower all-cause mortality and some cancers in metformin users vs non-diabetics, but design cannot separate drug effect from healthy-user/survivor bias. |
| Mehta V et al 2026 · study_type: meta-analysis | meta-analysis | mixed | low | Umbrella review, 5 studies, head & neck cancer. Metformin assoc w/ 0.74x survival (OS) vs non-users (95%CI 0.67-0.81); authors flag publication bias (Egger's test) and low confidence. |
| Jackson JW et al] # corrected 2026-08-17 from PubMed; was [Hernan 2018 · Cancer Epidemiol Biomarkers Prev | observational | contradicts | high | Methodological critique: action-focused/target-trial framing eliminates much of the spurious metformin-cancer signal seen in etiologic observational analyses. |
| Hiroki S et al 2026 · study_type: observational | observational | contradicts | high | Target trial emulation, metformin vs DPP-4i, T2D, Japan claims data. 5y CRC risk 1.55% vs 1.26%; RR 1.23 (0.91-1.66). No CRC benefit. |
| Shen X et al 2026 · study_type: observational | observational | mixed | moderate | Drug-target Mendelian randomization, 11 metformin-target genes vs 5 cancers. PRKAG1 (AMPK-gamma1) assoc w/ reduced CRC risk: OR 0.74 per mmol/mol HbA1c reduction (0.63-0.87, P=0.001), HbA1c-independent. |
| Powell 2025 · Am J Epidemiol | observational | contradicts | high | Target-trial emulation vs sulfonylureas accounting for biases: metformin did NOT reduce cancer incidence — well-designed null undercutting the protective claim. |
| Lei 2026 · Urol Oncol | meta-analysis | tested-null | moderate | Systematic review of 85 studies found no significant association between metformin and bladder cancer risk, a directional null against a protective claim. |
| Zhang S et al 2026 · study_type: meta-analysis | meta-analysis | tested-null | moderate | Meta-analysis of 5 RCTs, 705 patients, gynecologic cancers, metformin+standard therapy. PFS HR 0.76 (0.55-1.03, ns); OS HR 1.20 (0.88-1.62, ns). No survival benefit. |
| Szymczak-Pajor 2026 · Int J Mol Sci | meta-analysis | supports | low | Meta-analysis of 16 observational studies found metformin use associated with reduced pancreatic cancer risk versus other antidiabetic drugs. |
| O'Connor L et al] # corrected 2026-08-17 from PubMed; was [Petkovska 2024 · J Natl Cancer Inst | meta-analysis | mixed | moderate | Updated systematic review/meta: pooled observational data show lower cancer incidence with metformin, but authors stress residual confounding and bias limit causal inference. |
| Peerless Y et al 2026 · study_type: observational | observational | mixed | moderate | VA nested case-control, n=31,078 CRC cases/310,621 controls, diabetics. No effect right-sided CRC (OR~1.0); reduced left-sided CRC (OR 0.90, 0.82-0.98 at 1-3y; 0.87 at 3-5y). |
| Suissa 2012 · Diabetes Care | observational | contradicts | high | Demonstrates time-related (immortal-time, time-window) biases inflate apparent metformin anticancer benefit; correcting them largely abolishes the association. |
| Sacco M et al] # corrected 2026-08-17 from PubMed; was [Tsai 2023 · Viruses | observational | supports | low | Cohort in diabetic chronic-HCV patients: metformin use associated with reduced hepatocellular carcinoma; observational, confounding-prone. |
| Higurashi 2016 · Lancet Oncol | RCT | mixed | moderate | Only cancer-endpoint RCT: low-dose metformin modestly reduced metachronous colorectal adenoma recurrence in non-diabetics — small, single-center, surrogate (adenoma not cancer) endpoint. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.